Nivolumab vs Investigator'S Choice (IC) in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

被引：0

作者：

Ferris, Robert L. ^{[1
]}

Licitra, Lisa ^{[2
,3
]}

Fayette, Jerome ^{[4
]}

Even, Caroline ^{[5
]}

Blumenschein, George, Jr. ^{[6
]}

Harrington, Kevin J. ^{[7
]}

Guigay, Joel ^{[8
]}

Vokes, Everett E. ^{[9
]}

Saba, Nabil F. ^{[10
]}

Haddad, Robert ^{[11
]}

Ramkumar, Shanmugasundaram ^{[12
]}

Russell, Jeffery ^{[13
]}

Brossart, Peter ^{[14
]}

Tahara, Makoto ^{[15
]}

Monga, Manish ^{[16
]}

Zhu, Jin ^{[16
]}

Colevas, A. Dimitrios ^{[17
]}

Gillison, Maura L. ^{[18
]}

机构：

[1] Univ Pittsburgh, Med Ctr, Ctr Canc, Pittsburgh, PA USA

[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[3] Univ Milan, Milan, Italy

[4] Ctr Leon Berard, Lyon, France

[5] Gustave Roussy, Villejuif, France

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Inst Canc Res, Royal Marsden NHS Fdn Trust, London, England

[8] FHU OncoAge, Ctr Antoine Lacassagne, Nice, France

[9] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[11] Dana Farber Harvard Canc Ctr, Boston, MA USA

[12] NHS Fdn Trust, Univ Hosp Southampton, Southampton, Hants, England

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[14] Univ Hosp Bonn, Bonn, Germany

[15] Hosp East, Natl Canc Ctr, Kashiwa, Chiba, Japan

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Stanford Univ, Stanford, CA 94305 USA

[18] Ohio State Univ, Columbus, OH 43210 USA

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

214

引用

页码：143 / 143

页数：1

共 50 条

[1] Nivolumab (Nivo) vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
Ferris, Robert L.
Licitra, Lisa
Fayette, Jerome
Even, Caroline
Blumenschein, George R.
Harrington, Kevin
Guigay, Joel
Yokes, Everett E.
Saba, Nabil F.
Haddad, Robert I.
Ramkumar, Shanmugasundaram
Russell, Jeffrey
Brossart, Peter
Tahara, Makoto
Monga, Manish
Zhu, Jin
Colevas, A. Dimitrios
Gillison, Maura L.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Ferris, Robert L.
Licitra, Lisa
Fayette, Jerome
Even, Caroline
Blumenschein, George, Jr.
Harrington, Kevin J.
Guigay, Joel
Vokes, Everett E.
Saba, Nabil F.
Haddad, Robert
Ramkumar, Shanmugasundaram
Russell, Jeffery
Brossart, Peter
Tahara, Makoto
Colevas, A. Dimitrios
Concha-Benavente, Fernando
Lynch, Mark
Li, Li
Gillison, Maura L.
CLINICAL CANCER RESEARCH, 2019, 25 (17) : 5221 - 5230
[3] Nivolumab (nivo) vs investigator's choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
Saba, Nabil F.
Blumenschein, George R.
Guigay, Joel
Licitra, Lisa F.
Fayette, Jerome
Harrington, Kevin J.
Kiyota, Naomi
Gillison, Maura L.
Ferris, Robert L.
Jayaprakash, Vijayvel
Lynch, Mark John
Li, Li
Brossart, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141
Gillison, Maura L.
Blumenschein, George
Fayette, Jerome
Guigay, Joel
Colevas, A. Dimitrios
Licitra, Lisa
Harrington, Kevin
Kasper, Stefan
Vokes, Everett E.
Even, Caroline
Worden, Francis
Saba, Nabil F.
Docampo, Lara Carmen Iglesias
Haddad, Robert
Rordorf, Tamara
Kiyota, Naomi
Tahara, Makoto
Monga, Manish
Lynch, Mark
Geese, William J.
Schactman, Mark
Kopit, Justin
Shaw, James W.
Ferris, Robert L.
CANCER RESEARCH, 2016, 76
[5] Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
Saba, Nabil F.
Blumenschein, George, Jr.
Guigay, Joel
Licitra, Lisa
Fayette, Jerome
Harrington, Kevin J.
Kiyota, Naomi
Gillison, Maura L.
Ferris, Robert L.
Jayaprakash, Vijayvel
Li, Li
Brossart, Peter
ORAL ONCOLOGY, 2019, 96 : 7 - 14
[6] Nivolumab vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141
Licitra, L.
Ferris, R. L.
Blumenschein, G., Jr.
Harrington, K. J.
Guigay, J.
Kasper, S.
Saba, N. F.
Haddad, R.
Kiyota, N.
Monga, M.
Lynch, M.
Li, L.
Gillison, M. L.
Fayette, J.
ANNALS OF ONCOLOGY, 2017, 28
[7] Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.
Ferris, Robert L.
Blumenschein, George R.
Fayette, Jerome
Guigay, Joel
Colevas, A. Dimitrios
Licitra, Lisa F.
Harrington, Kevin J.
Kasper, Stefan
Vokes, Everett E.
Even, Caroline
Worden, Francis P.
Haddad, Robert I.
Kiyota, Naomi
Tahara, Makoto
Monga, Manish
Lynch, MarkJohn
Geese, William J.
Kopit, Justin
Shaw, James W.
Gillison, Maura L.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Efficacy and safety of nivolumab for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in Asia: CheckMate 141 subgroup analysis
Hasegawa, Y.
Kiyota, N.
Takahashi, S.
Yokota, T.
Yen, C-J.
Iwae, S.
Shimizu, Y.
Hong, R-L.
Goto, M.
Namba, Y.
Ferris, R. L.
Monga, M.
Lynch, M.
Hagihara, S.
Tahara, M.
ANNALS OF ONCOLOGY, 2016, 27
[9] Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator's choice (IC): CheckMate 141
Harrington, K.
Ferris, R. L.
Shaw, J.
Taylor, F.
Derosa, M.
Turner-Bowker, D.
Morrissey, L.
Cocks, K.
Kiyota, N.
Gillison, M.
Guigay, J.
ANNALS OF ONCOLOGY, 2016, 27
[10] Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (Nivo) or Investigator's Choice (IC): CheckMate 141
Kiyota, N.
Harrington, K.
Ferris, R. L.
Shaw, J. W.
Taylor, F.
Derosa, M.
Turner-Bowker, D.
Morrissey, L.
Cocks, K.
Gillison, M.
Guigay, J.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →